The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi’s (NASDAQ:SNY) lead drug candidate Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
The regulatory approval was supported by data readout from Phase 3 trial evaluating Dupixent, that met both primary and all secondary endpoints.
